文献速递重症综合管理与镇静镇痛复苏、休克与脓毒症

胰腺石蛋白即时免疫检测在ICU脓毒症诊断中的表现:前瞻性多中心生物标志物盲法研究

Diagnostic Performance of Point-of-Care Immunoassay Measurements of Pancreatic Stone Protein for Sepsis Detection in ICU Patients: A Prospective, Multicenter, Biomarker-Blinded Study.
PubMed 文献 · Crit Care Med · 2026-03-04
一句话结论在ICU入科前3天,胰腺石蛋白(PSP)以117 ng/mL为界值诊断脓毒症的灵敏度74.2%、特异度67.8%,联合C反应蛋白可将特异度提升至95.2%。

该多中心前瞻性观察性研究纳入美国6个ICU的466例预期需要至少24小时ICU治疗的成人患者,评估即时免疫检测胰腺石蛋白(PSP)在入ICU前3天内早期识别脓毒症的诊断性能。以约登指数确定PSP最佳界值为117 ng/mL,此时灵敏度74.2%、特异度67.8%、准确率71.0%、阳性预测值70.3%、阴性预测值71.9%、阳性似然比2.30、阴性似然比0.38。PSP联合C反应蛋白(CRP)将诊断特异度提高至95.2%。亚组分析显示性别间性能一致,18-60岁患者特异度更高;发热患者PSP特异度高(77.8%)但灵敏度较低(63.6%),非发热患者灵敏度76.6%、特异度67.0%。作者认为PSP可作为脓毒症早期识别生物标志物,联合CRP可提高诊断特异度。

要点

  • 在ICU入科前3天疑似脓毒症的成人中,PSP以117 ng/mL为界值诊断脓毒症的灵敏度74.2%、特异度67.8%、准确率71.0%。
  • PSP联合CRP可将诊断特异度从PSP单用的67.8%提升至95.2%。
  • 发热患者中PSP特异度77.8%、灵敏度63.6%;非发热患者灵敏度76.6%、特异度67.0%。
  • 18-60岁患者中PSP诊断特异度高于其他年龄组,性别间诊断性能一致。
  • PSP阳性似然比2.30、阴性似然比0.38,阴性结果对排除脓毒症有一定价值但不足以单独排除。

适用人群与场景

  • 美国6个ICU收治的成人患者,预期需要至少24小时ICU治疗,研究评估入ICU前3天内的脓毒症诊断。
  • 亚组分析涵盖不同性别、年龄(18-60岁及其他年龄)和发热状态的患者。

诊断标准与关键阈值

  • PSP最佳诊断界值为117 ng/mL,由约登指数确定。
  • 脓毒症诊断参照原文未具体说明的临床标准,研究以该界值识别脓毒症患者。

研究设计与关键结果

  • 多中心、前瞻性、观察性、生物标志物盲法研究,纳入466例成人ICU患者,来自美国6个ICU。
  • PSP界值117 ng/mL时诊断脓毒症的灵敏度74.2%、特异度67.8%、准确率71.0%、阳性预测值70.3%、阴性预测值71.9%、阳性似然比2.30、阴性似然比0.38。
  • PSP联合CRP将诊断特异度提高至95.2%。
  • 亚组分析:性别间性能一致;18-60岁患者特异度更高;发热患者PSP特异度77.8%、灵敏度63.6%;非发热患者灵敏度76.6%、特异度67.0%。

证据类型、等级与局限

  • 证据类型:多中心前瞻性观察性研究,生物标志物盲法设计。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为PSP可作为脓毒症早期识别的生物标志物,在不同年龄、性别和临床表现中具有广泛适用性。
  • 作者认为PSP联合CRP可提高脓毒症诊断特异度,提供互补方法以改善脓毒症检测并促进更早的适当管理。
  • 发热患者中PSP灵敏度较低(63.6%),阴性结果不能单独排除脓毒症;非发热患者中特异度较低(67.0%),阳性结果需结合临床判断。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: To evaluate the diagnostic performance of a rapid point-of-care immunoassay measuring pancreatic stone protein (PSP) for early sepsis identification within the first three days of ICU admission. Subgroup analyses (sex, age, febrile status) were conducted, and the combined diagnostic value of PSP and C-reactive protein (CRP) was assessed.

DESIGN: Multicenter, prospective, observational study.

PATIENT: Four hundred sixty-six adults the ICU.

SETTING: Six ICUs in the United States who were expected to required at least 24 hours of ICU care.

INTERVENTIONS: None.

MEASUREMENTS AND MAIN RESULTS: We calculated the Youden Index to evaluate the clinical performance of the PSP assay, and the resulting threshold was used to identify patients with sepsis. Diagnostic performance metrics included sensitivity, specificity, accuracy, positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio (LR+), and negative likelihood ratio (LR-). Receiver operating characteristic analysis were performed for PSP and CRP. At the optimal PSP cutoff point of 117 ng/mL, PSP demonstrated a sensitivity of 74.2%, specificity of 67.8%, accuracy of 71.0%, PPV of 70.3%, NPV of 71.9%, and LR+ and LR- ratios of 2.30 and 0.38, respectively. Combining PSP and CRP improved diagnostic specificity to 95.2%. Subgroup analyses demonstrated consistent performance across sex, and higher specificity was observed in patients 18-60 years old. In febrile patients, PSP achieved high specificity (77.8%) but lower sensitivity (63.6%). In non-febrile patients, specificity and sensitivity sensitivity and specificity were 67.0% and 76.6%, respectively.

CONCLUSIONS: PSP can serve as a biomarker for the early identification of sepsis. Diagnostic performance across diverse ages, sex, and clinical presentation supports the assay's broad applicability. The combination of PSP and CRP enhances diagnostic specificity for sepsis detection, offering a complementary approach to improve sepsis detection and lead to earlier appropriate management.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Shorr AF, Kollef MH, Wunderink RG, et al. Diagnostic Performance of Point-of-Care Immunoassay Measurements of Pancreatic Stone Protein for Sepsis Detection in ICU Patients: A Prospective, Multicenter, Biomarker-Blinded Study. Crit Care Med. 2026. PMID: 41778855. doi:10.1097/CCM.0000000000007087

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。